Neuro-healthtech pioneer CoMind has raised €85 million to bring its non-invasive brain monitoring technology to market — a system that measures key brain parameters without ever touching the skull.
The latest €51 million Series B, led by Plural with support from LocalGlobe, Latitude, Octopus Ventures, Crane, Angelini Ventures, and Lord David Prior, positions the company as one of Europe’s most heavily funded neuro-device startups to date. The capital will power U.S. clinical trials, FDA approvals, and global manufacturing partnerships as the company scales.
“James is a generational founder redefining how the brain is measured — and ultimately, how it’s treated,” said Julia Hawkins, General Partner at LocalGlobe and Latitude. “Partnering with him and the team has been one of our great privileges as investors.”
From Lasers, Not Drills
Founded in 2018 by James Dacombe at just 25 years old, CoMind has built the CoMind One, a breakthrough device that uses low-power laser light to track cerebral blood flow and intracranial pressure — parameters typically measured through invasive surgery.
Where traditional tools require drilling through the skull, CoMind’s optical approach uses photonics to capture real-time brain data safely, painlessly, and continuously. It’s designed for ICUs, surgical theatres, and neuro-critical care units, where early detection of changes in brain pressure can be life-saving.
“We’re replacing skull punctures with photons,” said Dacombe in a recent investor briefing. “That shift will change how every hospital monitors brain health.”
Advertisement
The Team and the Traction
The company’s leadership blends clinical and deep-tech expertise:
- Frank Fischer, Chair (ex-Intuitive Surgical Europe)
- Dr. Michael Tarnoff, former CEO of Tufts Medical Center
- Prof. Marc Bloom, Chief Medical Officer at the University of Miami
- Advisors from Johns Hopkins, Harvard Medical School, and Cleveland Clinic
The company aims for FDA approval by 2027. Its initial focus is traumatic brain injury (TBI) — a $10B global market that still relies heavily on invasive monitoring.
With over 50 million neuro-critical patients treated annually worldwide, CoMind’s non-invasive approach could become the clinical standard for brain monitoring, much like how Intuitive Surgical redefined robotic surgery.
Europe’s Neurotech Moment
CoMind’s €85M total funding places it among Europe’s largest neuro-device rounds of 2025, joining the ranks of startups like Rhovica Neuroimaging (€2.5M), Quibim (€47.9M), and Koios Care (€1M).
Investors see it as part of a larger shift: the convergence of AI, photonics, and neuro-engineering driving a new era of real-time, data-driven brain health.
“CoMind is doing for brain monitoring what pulse oximetry did for oxygen levels,” said Hawkins. “It’s the start of a new standard in how we understand — and protect — the human brain.”
About CoMind
CoMind is a London-based neuro-healthtech company developing non-invasive brain monitoring solutions for clinical and critical-care settings. Founded in 2018 by James Dacombe, the company’s flagship device, CoMind One, uses advanced photonics to measure key brain parameters safely and continuously — empowering hospitals, clinicians, and researchers with real-time insights into brain health.
